Novo Nordisk rises after Wegovy data

Zealand Pharma A/S

01/09/2025 08:51

** Shares in Novo Nordisk NOVOb.CO rise around 3% after the Danish drugmaker said its weight-loss drug Wegovy cuts heart risk by 57% versus rival treatments from Eli Lilly LLY.N

** Nordnet analyst Per Hansen points to the study as a reason for the share price move, though notes that question is how important the data is to investors

** "In reality, investors have not attached greater importance to these positive effects," Hansen says, adding that the weight loss has been the most important factor in terms of investment

** Novo's domestic peer Zealand Pharma ZELA.CO is up around 4% in early trade

** Up to previous session close, Novo stock was down around 43% YTD

 (Reporting by Elviira Luoma)

 ((Elviira.luoma@thomsonreuters.com))